Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/96258
Title: The impact of KRAS mutations on VEGF-A production and tumour vascular network
Author: Figueras, Agnès
Arbos, Maria Antonia
Quiles, Maria Teresa
Viñals Canals, Francesc
Germà Lluch, José Ramón
Capellá, G. (Gabriel)
Keywords: Endoteli
Tumors
Mutació (Biologia)
Angiogènesi
Endothelium
Tumors
Mutation (Biology)
Neovascularization
Issue Date: 18-Mar-2013
Publisher: BioMed Central
Abstract: Background: The malignant potential of tumour cells may be influenced by the molecular nature of KRAS mutations being codon 13 mutations less aggressive than codon 12 ones. Their metabolic profile is also different, with an increased anaerobic glycolytic metabolism in cells harbouring codon 12 KRAS mutations compared with cells containing codon 13 mutations. We hypothesized that this distinct metabolic behaviour could be associated with different HIF-1α expression and a distinct angiogenic profile. Methods: Codon13 KRAS mutation (ASP13) or codon12 KRAS mutation (CYS12) NIH3T3 transfectants were analyzed in vitro and in vivo. Expression of HIF-1α, and VEGF-A was studied at RNA and protein levels. Regulation of VEGF-A promoter activity was assessed by means of luciferase assays using different plasmid constructs. Vascular network was assessed in tumors growing after subcutaneous inoculation. Non parametric statistics were used for analysis of results. Results: Our results show that in normoxic conditions ASP13 transfectants exhibited less HIF-1α protein levels and activity than CYS12. In contrast, codon 13 transfectants exhibited higher VEGF-A mRNA and protein levels and enhanced VEGF-A promoter activity. These differences were due to a differential activation of Sp1/AP2 transcription elements of the VEGF-A promoter associated with increased ERKs signalling in ASP13 transfectants. Subcutaneous CYS12 tumours expressed less VEGF-A and showed a higher microvessel density (MVD) than ASP13 tumours. In contrast, prominent vessels were only observed in the latter. Conclusion: Subtle changes in the molecular nature of KRAS oncogene activating mutations occurring in tumour cells have a major impact on the vascular strategy devised providing with new insights on the role of KRAS mutations on angiogenesis.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/1471-2407-13-125
It is part of: BMC Cancer, 2013, vol. 13, num. 125
Related resource: http://dx.doi.org/10.1186/1471-2407-13-125
URI: http://hdl.handle.net/2445/96258
ISSN: 1471-2407
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
641776.pdf1.38 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons